Free Trial
NASDAQ:DAWN

Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis

Day One Biopharmaceuticals logo
$6.79 -0.40 (-5.56%)
Closing price 04:00 PM Eastern
Extended Trading
$6.80 +0.00 (+0.07%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Day One Biopharmaceuticals Stock (NASDAQ:DAWN)

Key Stats

Today's Range
$6.78
$7.13
50-Day Range
$6.16
$7.93
52-Week Range
$6.08
$16.76
Volume
1.15 million shs
Average Volume
1.15 million shs
Market Capitalization
$688.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.00
Consensus Rating
Buy

Company Overview

Day One Biopharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

DAWN MarketRank™: 

Day One Biopharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 719th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Day One Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Day One Biopharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Day One Biopharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Day One Biopharmaceuticals are expected to decrease in the coming year, from ($0.72) to ($0.97) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Day One Biopharmaceuticals is -9.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Day One Biopharmaceuticals is -9.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Day One Biopharmaceuticals has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Day One Biopharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    15.66% of the float of Day One Biopharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Day One Biopharmaceuticals has a short interest ratio ("days to cover") of 8.6.
  • Change versus previous month

    Short interest in Day One Biopharmaceuticals has recently decreased by 7.30%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Day One Biopharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Day One Biopharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.66% of the float of Day One Biopharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Day One Biopharmaceuticals has a short interest ratio ("days to cover") of 8.6.
  • Change versus previous month

    Short interest in Day One Biopharmaceuticals has recently decreased by 7.30%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Day One Biopharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for DAWN on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $167,298.00 in company stock.

  • Percentage Held by Insiders

    Only 6.20% of the stock of Day One Biopharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Day One Biopharmaceuticals' insider trading history.
Receive DAWN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DAWN Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

DAWN Stock Analysis - Frequently Asked Questions

Day One Biopharmaceuticals' stock was trading at $12.67 at the beginning of 2025. Since then, DAWN shares have decreased by 45.0% and is now trading at $6.9650.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) issued its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $0.11. The company had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million. Day One Biopharmaceuticals had a negative trailing twelve-month return on equity of 14.98% and a negative net margin of 42.66%.
Read the conference call transcript
.

Day One Biopharmaceuticals (DAWN) raised $126 million in an IPO on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Day One Biopharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Tesla (TSLA).

Company Calendar

Last Earnings
5/06/2025
Today
7/11/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DAWN
CIK
1845337
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$36.00
Low Price Target
$25.00
Potential Upside/Downside
+315.2%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.71)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$95.50 million
Net Margins
-42.66%
Pretax Margin
-38.25%
Return on Equity
-14.98%
Return on Assets
-13.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.62
Quick Ratio
10.55

Sales & Book Value

Annual Sales
$131.16 million
Price / Sales
5.40
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.99 per share
Price / Book
1.40

Miscellaneous

Outstanding Shares
101,360,000
Free Float
95,078,000
Market Cap
$708.00 million
Optionable
Optionable
Beta
-1.27
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:DAWN) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners